If you've been following aesthetic trends in 2026, you may have come across polynucleotides — sometimes called PDRN (polydeoxyribonucleotide) or PN — as the next significant development in regenerative aesthetics. The category has been used in Europe and Asia for years. It's now entering the US aesthetic market, and with it come both genuine clinical interest and the usual noise from early marketing.
Here's what the science and the regulatory situation actually look like.
What Polynucleotides Are
Polynucleotides are fragments of DNA, typically derived from salmon or trout DNA, that have been processed and sterilized for therapeutic use. Unlike hyaluronic acid, which primarily adds volume or hydration, polynucleotides work by interacting with cellular receptors (primarily adenosine A2A receptors) to stimulate tissue regeneration, fibroblast activity, and growth factor production.
The intended outcome: the skin rebuilds some of its own structural components through a biologically mediated process, rather than having them externally added. The result is improved skin quality — texture, tone, hydration, and density — over weeks to months as cellular activity increases.
This is distinct from both HA fillers (which add volume) and HA skin boosters like Skinvive (which primarily add hydration). Polynucleotides are theoretically closer to a regenerative tool than a volumizing or hydrating one.
What the Evidence Base Looks Like
The clinical literature on polynucleotides is more developed than on exosomes but less developed than on PRP or established HA products. Key findings from published studies:
•Multiple randomized controlled trials have shown significant improvement in skin texture, hydration, and elasticity compared to controls or saline
•Evidence is strongest for periorbital skin (around the eyes) and general facial skin quality
•Several studies show comparable or complementary results to HA skin boosters, with different mechanisms
•Two 2026 systematic reviews describe the evidence as promising but call for larger, longer-term, standardized trials
The evidence base supports genuine clinical benefit for skin quality applications. It's not yet at the level that would make polynucleotides a clearly preferred first choice over established options — PRP and HA skin boosters both have more clinical literature — but it's sufficient to explain why experienced providers are incorporating them.
The Regulatory Status in the US
This is the critical point that patients need to understand: as of mid-2026, there are no FDA-approved polynucleotide products for aesthetic use in the United States.
The products available and widely used in Europe and South Korea — Rejuran, PDRN fillers, various PN formulations — are not FDA-approved for the US market. They may be available at US practices through importation channels, as part of off-label use, or under investigational protocols, but they are not being sold with FDA-cleared labeling for aesthetic skin treatment.
This matters because:
•FDA approval requires demonstrating safety and efficacy through controlled clinical trials and meeting manufacturing and quality standards
•Products available through importation may not meet those standards
•Off-label use of an imported product without FDA approval is a different risk profile than off-label use of an FDA-approved product
Several companies are actively pursuing FDA approval for polynucleotide aesthetic products. The category may have approved options in the US within the next 1–3 years. In the meantime, practices offering polynucleotides are offering an investigational category without US regulatory backing.
That doesn't automatically make it dangerous — the international safety record is generally favorable — but it means you are not receiving the protections that FDA approval provides: verified manufacturing standards, controlled clinical efficacy data, and FDA adverse event monitoring.
How It Compares to PRP
PRP (platelet-rich plasma) is the most established regenerative injectable in aesthetic medicine, with multiple randomized controlled trials supporting its use for skin rejuvenation and hair restoration. PRP is derived from the patient's own blood, which eliminates concerns about sourcing, sterility of imported products, and most immunological reactions.
For patients interested in regenerative aesthetics who want a biologically driven approach with established regulatory standing, PRP is the current better-evidenced and better-regulated option in the US.
Polynucleotides may offer specific advantages in some contexts — particularly around the eyes, where the thin tissue may respond to their specific mechanism differently than to PRP — but the regulatory gap is real and should be part of your decision.
Questions to Ask If You're Considering This Treatment
•What specific product are you offering, and where is it manufactured?
•What is its regulatory status in the US?
•What is your clinical experience with this product?
•How does it compare to PRP for my specific concerns?
•What adverse events have you seen, and what is your protocol if I have a reaction?
A provider who can answer these questions clearly and who doesn't overstate the product's regulatory status is demonstrating the transparency that good practice requires in an emerging category.
This article is educational and reflects the regulatory status of polynucleotides as of mid-2026, which may change as FDA review processes advance. Consult a licensed medical professional for guidance.
Looking for a injectables provider?